The table shows the AUC for each algorithm, the lower and upper 95% confidence limits for the difference in areas (DP-SR) and the associated p-values.
After this adjustment the displayed confidence limits for the difference test may be used as a basis also for the visual representation of the equivalence test.
The CI limits for the difference in mean AUCs were exponentiated to yield the 90% CI for the ratio of geometric mean RaO AUCs of canagliflozin to placebo.
Without some adjustment, the confidence limits for the difference test would not give a valid visual representation for the equivalence test on the graph.
The lower 95% confidence limits for the difference in seroconversion between groups 10,447 IU, 3,013 IU, 587 IU and the reference group were 2.5%, -4.4%, and -5.5%, respectively.
The 95% confidence limits for the difference in plasma ADMA were −0.04-0.03 μmol/L, implying that any potential difference that we may have overlooked is likely to be within this range, which must be considered to be clinically unimportant.
The 95% CI upper limits for the difference in SCRs (control minus Flu-50) for the 18 to 35 months age strata were 10.48%, 9.02% and -0.43% respectively for the A/Brisbane (H1N1), A/Uruguay (H3N2) and B/Florida strains.
The table shows the mean recall for each algorithm, the lower and upper 95% confidence limits for the difference in recall (DP-SaTScan™) and the associated t-test p-values Comparison of the DP and SaTScan™ spatial recall.
After shifting all relevant values to the new zero baseline, the confidence limits for the difference test on this new scale become: mG - mC ± lsd GC 1 95), the equivalence limits mR - mC ± lsd(GR 2 97.5), and the confidence limits for the equivalence tests E2 and E3 mG - mC ± lsd(GR 1 95).
